Opioid addiction: long-acting formulations for a long-term disorder

Affiliations

¹ Lovisenberg Diaconal Hospital, 0440 Oslo, Norway. Electronic address: nku@lds.no.
² NYU School of Medicine, Department of Population Health, New York, NY, USA.

Comment

Nikolaj Kunøe et al. Lancet. 2019.

. 2019 Feb 23;393(10173):723-724.

doi: 10.1016/S0140-6736(18)32428-0. Epub 2019 Feb 18.

¹ Lovisenberg Diaconal Hospital, 0440 Oslo, Norway. Electronic address: nku@lds.no.
² NYU School of Medicine, Department of Population Health, New York, NY, USA.

No abstract available

Comment on

Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Haight BR, Learned SM, Laffont CM, Fudala PJ, Zhao Y, Garofalo AS, Greenwald MK, Nadipelli VR, Ling W, Heidbreder C; RB-US-13-0001 Study Investigators. Haight BR, et al. Lancet. 2019 Feb 23;393(10173):778-790. doi: 10.1016/S0140-6736(18)32259-1. Epub 2019 Feb 18. Lancet. 2019. PMID: 30792007 Clinical Trial.